Payment overview · 2025
General Payments
$1,938.86
121 reported records · 27 companies
Healthcare provider profile · identity verified
Brian Joseph Leblanc, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW ROADS, LA · NPI 1609876473
Verified facts
What the public records show
CMS Open Payments records show Brian Joseph Leblanc, M.D. received $1,938.86 in general payments during 2025 across 121 reported records.
ABBVIE INC. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $308.98 | 15.9% | 33 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $199.15 | 10.3% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $149.07 | 7.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.85 | 7.1% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.59 | 7.0% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $107.33 | 5.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.21 | 5.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $96.54 | 5.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.44 | 4.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.05 | 3.6% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.44 | 2.6% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.92 | 2.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.02 | 2.2% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.63 | 2.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.89 | 2.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.86 | 2.1% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $37.50 | 1.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.98 | 1.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.74 | 1.7% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.97 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.70 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.44 | 1.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.40 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.46 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.74 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.00 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.96 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,938.86 | 121 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.40 | 19 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $164.40 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $164.29 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $149.07 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.85 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $137.85 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.58 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $116.41 | 12 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $107.33 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $96.54 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.05 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.64 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.64 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.44 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.92 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.57 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.57 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $41.63 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $37.50 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.44 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $12.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 472 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 81 |
| Gabapentin | Gabapentin | 265 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 65 |
| Meloxicam | Meloxicam | 247 | 72 |
| Potassium Chloride | Potassium Chloride | 232 | 56 |
| Metformin Hcl | Metformin Hcl | 214 | 66 |
| Trazodone Hcl | Trazodone Hcl | 213 | 52 |
| Simvastatin | Simvastatin | 198 | 47 |
| Furosemide | Furosemide | 196 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 53 |
| Alprazolam | Alprazolam | 166 | 26 |
| Sertraline Hcl | Sertraline Hcl | 163 | 41 |
| Omeprazole | Omeprazole | 128 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 46 |
| Losartan Potassium | Losartan Potassium | 120 | 36 |
| Mounjaro | Tirzepatide | 115 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 33 |
| Allopurinol | Allopurinol | 109 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 29 |
| Lisinopril | Lisinopril | 100 | 33 |
| Lorazepam | Lorazepam | 99 | 23 |
| Alendronate Sodium | Alendronate Sodium | 93 | 24 |
| Montelukast Sodium | Montelukast Sodium | 93 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 22 |
| Azithromycin | Azithromycin | 77 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 25 |
| Ozempic | Semaglutide | 71 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Jardiance | Empagliflozin | 63 | 13 |
| Prednisone | Prednisone | 63 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 18 |
| Carvedilol | Carvedilol | 55 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Januvia | Sitagliptin Phosphate | 55 | 15 |
| Buspirone Hcl | Buspirone Hcl | 54 | 11 |
| Levofloxacin | Levofloxacin | 54 | 46 |
| Metformin Hcl Er | Metformin Hcl | 54 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 46 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 12 |
| Eliquis | Apixaban | 49 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Glipizide Er | Glipizide | 48 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Colchicine | Colchicine | 41 | suppressed |
| Linzess | Linaclotide | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 24 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 15 |
| Synthroid | Levothyroxine Sodium | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 27 |
| Atenolol | Atenolol | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 13 |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 16 |
| Nystatin | Nystatin | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,938.86 · 121 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, Azstarys, BEYFORTUS, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, GARDASIL 9, INGREZZA, JARDIANCE, Jornay PM, Kerendia, MENQUADFI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error